Carciongenesis III Flashcards

1
Q

Discovery of oncogenes

A
  1. observing oncogenic retroviruses
    - gag gene– internal virion protein
    - env gene– virus membrane glycoporoteins
    - pol gene– virus polymerase
    - - harmless by themselves but replicate and transmitted in the host cell genome through somatic or sex cells
  2. more oncogenes in retroviruses
    - v-onc segment–> ability to rapidly transform infected cells to malignant phenotype
    - v-src–> oncogene or Rous Sarcoma virus–> fibrosarcomas in birds
    - v-erb–> oncogene of avian erythroblastosis virus–> erythrobalstosis in chickens
    - v-abl–> oncogene in Abelson leukemia virus from mice
    - v-myc–> fused with gag gene, capable of eliciting neoplastic transformations.
  3. cellular transformation check
  4. assayed by tumor formation in animals after oncogenic virus
  5. transformation of cell morphology and growth regulation after infection of cultured cells in vitro
  6. foci of infected cells develop as clones can be counted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

viral oncogenes proteins

A
  1. pp60v-src by v-src gene
  2. v-erb-B protein
  3. v-able protein
  4. v-able protein
  5. c-src protein
  6. c-myc protein
  7. c-ras
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pp60v-src protein

A

membrane bound protein kinase phosphorylating the tyrosine residues in different proteins, affecting gene expression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

v-erb-B protein

A
  • similar structure to receptor for epidermal growth factor (EGFR)
  • tyrosine specific protein kinase activity
  • growth simulating protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

v-able protein

A
  • protein kinase phosphorylating tyrosine residue on other proteins
  • similar to c-ABL in BCR-ABL translocation in Philadelphia chromosome
  • over-expressed in BCR-ABL CML(chronic myeloid leukemia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

c-src

A
  • different carboxy terminal aa than v-src

- more introns

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

c-myc

A
  • many introns more than v-myc, almost identical
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

substantial rearrangement

A

c-onc to v-onc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

oncogenes as molecular markers in prognosis

A

oncogenes and tumor suppressors are good markers for cancer diagnosis and prognosis

  • oncogene–> amplified
  • tumor suppressor–> reduced
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

example of molecular marker for prognosis (c-ras gene)

A

detection of c-ras gene

  • poor prognosis
  • point mutation for human bladder cancer cell
  • mutations in codon 12 or codon 61 of the ras gene
  • detection of ras mutaiton–> poor diagnosis
  • qualitative model (overactive protein)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

example of molecular marker for prognosis (amplification of c-onc genes)

A

amplification of c-onc genes

  • poor diagnosis
  • n-myc amplification in neuroblastoma
  • HER2/neu oncogene amplification about 20% in breast cancer
  • quantitative model (too much protein)
  • good because targeted drug can be designed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

example of molecular marker for prognosis

translocations of c-onc

A

detection of translocations of c-onc gene

  • poor diagnosis
  • qualitative model (over expression)
  • Burkitt lymphoma
  • philadelphia chromosome (BCR-ABL translocation)
  • good because targeted drug can be desgined
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Def of oncogene

A
  • normally stimulate cellular proliferation

- mutation activates oncogene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Def of tumor suppressor

A
  • normally inhabit cellular proliferation

- mutation deactivates tumor suppressor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

oncogene and tumor suppressor contribution to cancers

A
  • both bush mutations
  • loss of growth regulation
  • increased mutation rate
  • loss of apoptosis in colon cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

molecular targeted therapy or rationally designed drug therapy

A

identify the defect in the tumor and target that specific defect to fix it

17
Q

therapy for amplification of HER2/neu/erb2

A

monoclonal antibodies for HER2/neu/erbB2 protein

  • Herceptin (the antibodies)
  • reverse the cancer phenotype
  • extend the life of breast cancer patients
18
Q

therapy for RB negative small cell lung cancer

A

Injection of RB gene

- inhabit tumorigenesis

19
Q

therapy for p53 cancer cell

A

E1B mutant adenoviruses

  • kill p53 cancer cell selectively
  • cannot inactivated p53 so cannot kill wild type cell
20
Q

therapy for dominant negative p53 mutations

A

drug correcting mutant conformation

21
Q

therapy for BCR-ABL translocation (Philadelphia chromosome)

A

Gleevac (ATP analog)

  • inhabit the ABL tyrosine kinase
  • no other ATPase inhabited
22
Q

Bioinformatics

A

For targeted therapy and for “personalized medicine” in cancer

23
Q

Heat map

A
  • correlation of molecular data ( gene copy number, gene expression, mutations)
  • relevant clinical info ( tumor grade, survival, age, tumor stage)
  • red–> increase
  • blue–> reduced
24
Q

more examples of personalized medicine

A
  • high erbB2 targeted with Herceptin (mentioned before)

- high estrogen receptor level treated with tamoxifen (estrogen antagonist)

25
Q

the tool that made cancer therapy very personal design

A

Whole genome sequencing

  • personal basis on type of mutations (ocogene vs tumor suppressor vs etc)
  • decide the therapy based on case by case according to patient’s bioinformatics